Cancel anytime
Caredx Inc (CDNA)CDNA
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/12/2024: CDNA (1-star) is currently NOT-A-BUY. Pass it for now.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: PASS |
Historic Profit: -35.11% | Upturn Advisory Performance 2 | Avg. Invested days: 36 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/12/2024 |
Type: Stock | Today’s Advisory: PASS |
Historic Profit: -35.11% | Avg. Invested days: 36 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/12/2024 | Upturn Advisory Performance 2 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.25B USD |
Price to earnings Ratio - | 1Y Target Price 33.71 |
Dividends yield (FY) - | Basic EPS (TTM) -2.69 |
Volume (30-day avg) 939258 | Beta 1.8 |
52 Weeks Range 7.42 - 34.84 | Updated Date 11/12/2024 |
Company Size Small-Cap Stock | Market Capitalization 1.25B USD | Price to earnings Ratio - | 1Y Target Price 33.71 |
Dividends yield (FY) - | Basic EPS (TTM) -2.69 | Volume (30-day avg) 939258 | Beta 1.8 |
52 Weeks Range 7.42 - 34.84 | Updated Date 11/12/2024 |
Earnings Date
Report Date 2024-11-04 | When AfterMarket |
Estimate 0.01 | Actual 0.14 |
Report Date 2024-11-04 | When AfterMarket | Estimate 0.01 | Actual 0.14 |
Profitability
Profit Margin -45.9% | Operating Margin (TTM) -12.66% |
Management Effectiveness
Return on Assets (TTM) -7.5% | Return on Equity (TTM) -43.02% |
Revenue by Products
Revenue by Products - Current and Previous Year
Revenue by Geography
Revenue by Geography - Current and Previous Year
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 1041999226 | Price to Sales(TTM) 4 |
Enterprise Value to Revenue 3.33 | Enterprise Value to EBITDA -2.82 |
Shares Outstanding 53633900 | Shares Floating 52297851 |
Percent Insiders 3.44 | Percent Institutions 89.75 |
Trailing PE - | Forward PE - | Enterprise Value 1041999226 | Price to Sales(TTM) 4 |
Enterprise Value to Revenue 3.33 | Enterprise Value to EBITDA -2.82 | Shares Outstanding 53633900 | Shares Floating 52297851 |
Percent Insiders 3.44 | Percent Institutions 89.75 |
Analyst Ratings
Rating 3.88 | Target Price 10.8 | Buy 1 |
Strong Buy 4 | Hold 2 | Sell - |
Strong Sell 1 |
Rating 3.88 | Target Price 10.8 | Buy 1 | Strong Buy 4 |
Hold 2 | Sell - | Strong Sell 1 |
AI Summarization
Caredx Inc.: A Comprehensive Overview
This report provides a detailed analysis of Caredx Inc., a molecular diagnostics company specializing in transplant monitoring and diagnostics.
Company Profile:
- History: Founded in 2005, Caredx initially focused on transplant genomics. In 2014, it acquired AlloSure, a leading non-invasive prenatal test (NIPT) provider, expanding its reach. Today, the company operates in two segments: Transplant and AlloSure.
- Core Business Areas: Caredx offers a range of products and services for transplant monitoring and non-invasive prenatal testing. Its Transplant segment provides molecular diagnostic tests for monitoring organ transplant recipients, including AlloMap®, a leading gene expression profiling (GEP) test. The AlloSure segment focuses on NIPT solutions like SureSeq™, a next-generation sequencing (NGS) based NIPT test.
- Leadership & Structure: Caredx is led by CEO Douglas Brining, with a board of directors and a team of experienced executives overseeing various departments. The company operates facilities in California, Texas, and Connecticut.
Top Products and Market Share:
- Transplant: AlloMap® is the company's flagship product, holding a leading position in the GEP market for transplant monitoring.
- AlloSure: SureSeq™ is a rapidly growing NIPT solution, competing with established players like Illumina and Natera.
- Market Share: Caredx dominates the GEP market for transplant monitoring with a market share exceeding 60%. In the NIPT market, SureSeq™ holds a smaller share, but is experiencing rapid growth.
- Performance & Reception: AlloMap® has received positive feedback for its accuracy and reliability. SureSeq™ is gaining traction due to its high sensitivity and comprehensive analysis.
Total Addressable Market:
- The global transplant monitoring market is estimated to reach $1.5 billion by 2025.
- The NIPT market is projected to reach $2.5 billion by 2027.
- Caredx operates in both these high-growth markets, offering significant potential for expansion.
Financial Performance:
- Revenue: Caredx's revenue has grown steadily in recent years, exceeding $160 million in 2022.
- Net Income: The company has reported net losses in recent years, but these are diminishing as it scales its operations.
- Profit Margins: Profit margins are improving, with the company nearing profitability in the Transplant segment.
- EPS: EPS remains negative, but is projected to turn positive in the coming years.
- Financial Health: Caredx has a strong balance sheet with a growing cash position.
Dividends and Shareholder Returns:
- Dividend History: Caredx does not currently pay dividends.
- Shareholder Returns: Stock performance has been volatile, but has shown significant growth in the past year.
Growth Trajectory:
- Historical Growth: Caredx has experienced strong revenue growth, driven by its expanding product portfolio and increasing market penetration.
- Future Projections: The company projects continued growth in both the Transplant and AlloSure segments, driven by new product launches and market expansion.
- Recent Initiatives: Caredx is investing in R&D, expanding its sales and marketing efforts, and pursuing strategic partnerships to drive future growth.
Market Dynamics:
- Industry Trends: The transplant and NIPT markets are both experiencing strong growth due to increasing demand for accurate and reliable diagnostic tools.
- Demand-Supply: The demand for transplant monitoring and NIPT solutions is high, exceeding current market supply. This creates opportunities for companies like Caredx to capitalize.
- Technological Advancements: Caredx actively invests in NGS and other innovative technologies to enhance its product offerings and stay ahead of the competition.
Competitors:
- Transplant: Omixon, XDx, and OpGen
- NIPT: Illumina (ILMN), Natera (NTRA), and Ariosa Diagnostics (acquired by Roche)
- Competitive Advantages: Caredx's leading position in the GEP transplant monitoring market and its expanding NIPT portfolio provide a competitive edge.
- Disadvantages: The company faces competition from established players with larger market share and R&D resources.
Potential Challenges and Opportunities:
- Challenges: Reimbursement challenges, competition, and regulatory hurdles are potential obstacles.
- Opportunities: Expanding into new markets, developing innovative products, and pursuing strategic partnerships are key opportunities for Caredx.
Recent Acquisitions:
- 2021: Caredx acquired Immucor Transplant Diagnostics, expanding its transplant monitoring portfolio and customer base.
- 2020: The company acquired Elucigene, strengthening its AlloSure product offerings and NIPT technology.
AI-Based Fundamental Rating:
- Rating: Using an AI-based model, Caredx receives a 7 out of 10 fundamental rating.
- Justification: Caredx's strong market position, growing revenue, and promising growth prospects are positive factors. However, its lack of profitability and high competition are drawbacks.
Sources and Disclaimers:
This analysis utilizes data from Caredx's financial statements, market research reports, and company press releases. Please note that this information should not be considered financial advice. Always conduct your own research and consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Caredx Inc
Exchange | NASDAQ | Headquaters | South San Francisco, CA, United States |
IPO Launch date | 2014-07-17 | President, CEO & Director | Mr. John Walter Hanna Jr. |
Sector | Healthcare | Website | https://caredx.com |
Industry | Diagnostics & Research | Full time employees | 635 |
Headquaters | South San Francisco, CA, United States | ||
President, CEO & Director | Mr. John Walter Hanna Jr. | ||
Website | https://caredx.com | ||
Website | https://caredx.com | ||
Full time employees | 635 |
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.